GRAIL (NASDAQ: GRAL) plans corporate update at J.P. Morgan event

Rhea-AI Filing Summary

GRAIL, Inc. reported that it plans to present a corporate update and preliminary financial information for the quarter and year ended December 31, 2025 at the 2026 J.P. Morgan Healthcare Conference. The company states that the slide presentation to be used at the conference is being furnished as Exhibit 99.1 to this current report. The company clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, meaning it is not subject to certain liabilities under the Securities Exchange Act and will not be incorporated by reference into other SEC filings unless specifically referenced. The report is signed on behalf of GRAIL by its Chief Financial Officer, Aaron Freidin.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001699031FALSE00016990312026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________________

FORM 8-K

_____________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

_____________________________________________

GRAIL, Inc.

(Exact Name of Registrant as Specified in Charter)

___________________________________________

Delaware			001-42045			86-3673636
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

1525 O’Brien Drive Menlo Park, California 94025

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (833) 694-2553

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

GRAL

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02 Results of operations and financial condition.

On January 12, 2026, GRAIL, Inc. (the “Company”) plans to present a corporate update and preliminary financial information for the quarter and year ended December 31, 2025 at the 2026 J.P. Morgan Healthcare Conference. A copy of the presentation that will be used is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K and the exhibit attached hereto are intended to be “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Except as shall be expressly set forth by specific reference in such filing, the information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01    Exhibits.

(d) Exhibits.

99.1* Results of operations and financial condition.

____________

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GRAIL, INC.

Date:

January 12, 2026

By:

/s/ Aaron Freidin

Name:

Aaron Freidin

Title:

Chief Financial Officer

FAQ

What did GRAIL (GRAL) disclose in this 8-K filing?

GRAIL disclosed that it plans to present a corporate update and preliminary financial information for the quarter and year ended December 31, 2025 at the 2026 J.P. Morgan Healthcare Conference, with the related presentation furnished as Exhibit 99.1.

What time period does GRAIL’s preliminary financial information cover?

The preliminary financial information to be discussed by GRAIL covers the quarter and year ended December 31, 2025.

What is Exhibit 99.1 in GRAIL’s 8-K for GRAL?

Exhibit 99.1 is the presentation GRAIL plans to use for its corporate update and preliminary financial information at the 2026 J.P. Morgan Healthcare Conference, and it is furnished with this report.

Is the GRAIL (GRAL) conference presentation considered filed with the SEC?

No. GRAIL states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Will the information in this GRAIL 8-K automatically be incorporated into other SEC filings?

No. GRAIL specifies that the information in this report and its exhibit will not be incorporated by reference into other SEC filings unless expressly set forth by specific reference.

Who signed this GRAIL (GRAL) 8-K filing?

The report was signed on behalf of GRAIL, Inc. by Aaron Freidin, who is identified as the company’s Chief Financial Officer.